Fulvestrant: A review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy

Drugs

Volumn 64, Issue 6, 2004, Pages 633-648

  McKeage, Kate ^a   Curran, Monique P ^a   Plosker, Greg L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; CYTOCHROME P450 3A4; ESTROGEN RECEPTOR; ETHINYLESTRADIOL; FULVESTRANT; GEFITINIB; HORMONE RECEPTOR; KETOCONAZOLE; LETROZOLE; MIDAZOLAM; RALOXIFENE; RIFAMPICIN; SOMATOMEDIN; TAMOXIFEN; TOREMIFENE;

ARTHRALGIA; ARTHRITIS; ASTHENIA; BLEEDING; BREAST CANCER; BREAST METASTASIS; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; ENDOMETRIUM; ENDOMETRIUM CANCER; ENZYME INHIBITION; GENE CONTROL; GENETIC TRANSCRIPTION; HEADACHE; HOT FLUSH; HUMAN; INFLAMMATION; INJECTION PAIN; INJECTION SITE; NAUSEA; OSTEOARTHRITIS; PAIN; POSTMENOPAUSE; QUALITY OF LIFE; RECEPTOR DOWN REGULATION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; TREATMENT FAILURE; VASODILATATION;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CLINICAL TRIALS; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; NEOPLASM METASTASIS; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; POSTMENOPAUSE; TAMOXIFEN; TRIAZOLES;

EID: 1842785010     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464060-00009     Document Type: Review

References (61)

1. American Cancer Society. Breast cancer facts & figures 2003-2004 [online]. Available from URL: http://www.cancer.org [Accessed 2003 Nov 6]
2. Peto R. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years [letter]. Lancet 2000; 355: 1822
3. Dhingra K. Selective estrogen receptor modulation: the search for an ideal hormonal therapy for breast cancer. Cancer Invest 2001; 19 (6): 649-59
4. Buzdar AU. Endocrine therapy in the treatment of metastatic breast cancer. Semin Oncol 2001; 28 (3): 291-304
5. Pritchard KI. Endocrine therapy of advanced disease: analysis and implications of the existing data. Clin Cancer Res 2003 Jan; 9 (1 Pt 2): 460S-7S
6. Curran M, Wiseman L. Fulvestrant. Drugs 2001; 61 (6): 807-13
7. Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res 1991; 51 (15): 3867-73
8. Wakeling AE, Bowler J. Steroidal pure antioestrogens. J Endocrinol 1987; 112 (3): R7-R10
9. Parker MG. Action of 'pure' antiestrogens inhibiting estrogen receptor action. Breast Cancer Res Treat 1993; 26: 131-7
10. Fawell SE, White R, Hoare S, et al. Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc Natl Acad Sci U S A 1990; 87: 6883-7
11. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 1995; 87: 746-50
12. Gibson MK, Nemmers LA, Beckman WC, et al. The mechanism of ICI 164384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue. Endocrinology 1991; 129: 2000-10
13. Dauvois S, White R, Parker MG. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 1993 Dec; 106: 1377-88
14. Dauvois S, Danielian PS, White R, et al. Antiestrogenic ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci U S A 1992; 89: 4037-41
15. DeFriend DJ, Howell A, Nicholson RI, et al. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res 1994; 54: 408-14
16. Robertson JF, Nicholson RI, Bundred NJ, et al. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl) -nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res 2001 Sep 15; 61 (18): 6739-46
17. Nuttall ME, Pendrak I, Emery JG, et al. Antagonism of oestrogen action in human breast and endometrial cells in vitro: potential novel antitumour agents. Cancer Chemother Pharmacol 2001 May; 47 (5): 437-43
18. Addo S, Yates RA, Laight A. A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers. Br J Cancer 2002 Dec 2; 87 (12): 1354-9
19. Howell A, DeFriend DJ, Robertson JFR, et al. Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer. Br J Cancer 1996; 74: 300-8
20. Dukes M, Miller D, Wakeling AE, et al. Antiuterotrophic effects of a pure antioestrogen, ICI 182,780: magnetic resonance imaging of the uterus in ovariectomized monkeys. J Endocrinol 1992; 135 (2): 239-47
21. Dukes M, Waterton JC, Wakeling AE. Antiuterotrophic effects of the pure antioestrogen ICI 182,780 in adult female monkeys (Macaca nemestrina): quantitative magnetic resonance imaging. J Endocrinol 1993; 138: 203-9
22. Sato K, Nohtomi K, Shizume K, et al. 17 beta-estradiol increases calcium content in fetal mouse parietal bones cultured in serum-free medium only at physiological concentrations. Bone 1996; 19 (3): 213-21
23. Gunther DF, Calikoglu AS, Underwood LE. The effects of the estrogen receptor blocker, Faslodex (ICI 182,780), on estrogen-accelerated bone maturation in mice. Pediatr Res 1999; 46 (3): 269-73
24. Gunther DF, Underwood LE, Calikoglu AS. Androgen-accelerated bone maturation in mice is not attenuated by Faslodex, an estrogen receptor blocker. Bone 2001 Apr; 28 (4): 410-3
25. Gallagher A, Chambers TJ, Tobias JH. The estrogen antagonist ICI 182,780 reduces cancellous bone volume in female rats. Endocrinology 1993; 133: 2787-91
26. Thomas EJ, Walton PL, Thomas NM, et al. The effects of ICI 182,780, a pure anti-oestrogen, on the hypothalamic-pituitary-gonadal axis and on endometrial proliferation in pre-menopausal women. Hum Reprod 1994; 9: 1991-6
27. Long BJ, Tilghman SL, Yue W, et al. The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity. J Steroid Biochem Mol Biol 1998; 67: 293-304
28. Huynh H, Nickerson T, Pollak M, et al. Regulation of insulin-like growth factor I receptor expression by the pure antiestrogen ICI 182780. Clin Cancer Res 1996; 2: 2037-42
29. Chan TW, Pollak M, Huynh H. Inhibition of insulin-like growth factor signaling pathways in mammary gland by pure antiestrogen ICI 182,780. Clin Cancer Res 2001 Aug; 7 (8): 2545-54
30. Hyder SM, Stancel GM. Inhibition of progesterone-induced VEGF production in human breast cancer cells by the pure antiestrogen ICI 182,780. Cancer Lett 2002 Jul 8; 181 (1): 47-53
31. Dick GM. The pure anti-oestrogen ICI 182,780 (Faslodex™) activates large conductance Ca(2+)-activated K(+) channels in smooth muscle. Br J Pharmacol 2002 Aug; 136 (7): 961-4
32. Bundred N, Anderson E, Nicholson RI, et al. ICI 182,780 (Faslodex) an estrogen receptor downregulator reduces cell turnover index more effectively than tamoxifen [abstract no. 1660]. 37th Annual Meeting of the Am Soc Clin Oncol 2001 May 12; 20 Pt 1: 416
33. Bundred N, Howell A. Fulvestrant (Faslodex): current status in the therapy of breast cancer. Expert Rev Anticancer Ther 2002 Apr; 2 (2): 151-60
34. de Cupis A, Noonan D, Pirani P, et al. Comparison between novel steroid-like and conventional nonsteroidal antioestrogens in inhibiting oestradiol- and IGF-I-induced proliferation of human breast cancer-derived cells. Br J Pharmacol 1995; 116: 2391-400
35. Lykkesfeldt AE, Madsen MW, Briand P. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1. Cancer Res 1994; 54: 1587-95
36. Lykkesfeldt AE, Larsen SS, Briand P. Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment. Int J Cancer 1995; 61: 529-34
37. DeFriend DJ, Anderson E, Bell J, et al. Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro. Br J Cancer 1994; 70: 204-11
38. Coradini D, Biffi A, Cappelletti V, et al. Activity of tamoxifen and new antiestrogens on estrogen receptor positive and negative breast cancer cells. Anticancer Res 1994; 14: 1059-64
39. Bundred NJ, Anderson E, Nicholson RI, et al. Fulvestrant, an estrogen receptor downregulator, reduces cell turnover index more effectively than tamoxifen. Anticancer Res 2002 Jul; 22 (4): 2317-20
40. Hu XF, Veroni M, De Luise M, et al. Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182, 780. Int J Cancer 1993; 55: 873-6
41. Osborne CK, Jarman M, McCague R, et al. The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemother Pharmacol 1994; 34: 89-95
42. Varma H, Conrad SE. Antiestrogen ICI 182,780 decreases proliferation of insulin-like growth factor I (IGF-I)-treated MCF-7 cells without inhibiting IGF-I signaling. Cancer Res 2002 Jul 15; 62 (14): 3985-91
43. Lim KB, Ng CY, Ong CK, et al. Induction of apoptosis in mammary gland by a pure anti-estrogen ICI 182780. Breast Cancer Res Treat 2001 Jul; 68: 127-38
44. Diel P, Smolnikar K, Michna H. The pure antiestrogen ICI 182780 is more effective in the induction of apoptosis and down regulation of BCL-2 than tamoxifen in MCF-7 cells. Breast Cancer Res Treat 1999; 58 (2): 87-97
45. Ellis PA, Saccani-Jotti G, Clarke R, et al. Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer. Int J Cancer 1997; 72 (4): 608-13
46. Erikstein B, Robertson JF, Osborne CK, et al. ICI 182,780 (faslodex) 250 mg monthly intramuscular injection shows consistent PK profile when given as either 1 X 5ml or 2 X 2.5 MI injections in postmenopausal women with advanced breast cancer [abstract no. 2025]. 37th Annual Meeting of the Am Soc Clin Oncol 2001 May 12; 20 Pt 2: 69
47. Robertson JF, Harrison MP. Equivalent single-dose pharmacokinetics of two different dosing methods of prolonged-release fulvestrant (Faslodex) in postmenopausal women with advanced breast cancer. Cancer Chemother Pharmacol 2003 Oct; 52 (4): 346-8
48. AstraZeneca. Faslodex: fulvestrant injection [online]. Available from URL: http://www.astrazeneca.com [Accessed 2003 Nov 5]
49. Harrison M, Laight A, Clarke D, et al. Pharmacokinetics and metabolism of fulvestrant after oral, intravenous and intramuscular administration in healthy volunteers [abstract no. 564]. Eur J Cancer 2003; 1 Suppl. 5: S171
50. Laight A, Yates R, Rose A, et al. Fulvestrant is unlikely to be involved in clinically significant drug interactions - results of clinical trials in healthy male volunteers [abstract no. 133]. Proc Am Soc Clin Oncol 2003; 22: 33
51. Howell A, Robertson JFR, Quaresma Albano J, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002 Aug 15; 20 (16): 3396-403
52. Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002 Aug 15; 20 (16): 3386-95
53. Robertson JF, Osborne CK, Howell A, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 2003 Jul 15; 98 (2): 229-38
54. Mauriac L, Pippen JE, Quaresma Albano J, et al. Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials. Eur J Cancer 2003 Jun; 39 (9): 1228-33
55. Pippen J, Osborne CK, Howell A, et al. Fulvestrant (Faslodex) versus anastrozole (Arimidex) for the treatment of advanced breast cancer: a prospective combined survival analysis of two multicenter trials [abstract no. 426]. 26th Annual San Antonio Breast Cancer Symposium; 2003 Dec 3-6; San Antonio (TX). Available from URL: http://www.sabcs.org/
56. Morrow M, Gradishar W. Recent developments: breast cancer. BMJ 2002; 324: 410-4
57. Morris C, Wakeling A. Fulvestrant ('Faslodex'): a new treatment option for patients progressing on prior endocrine therapy. Endocr Relat Cancer 2002 Dec; 9 (4): 267-76
58. National Comprehensive Cancer Network. Clinical pratice guidelines in oncology: breast cancer [online]. Available from URL: http://www.nccn.com [Accessed 2003 Dec 3]
59. Love RR, Barden HS, Mazess RB, et al. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Intern Med 1994; 154: 2585-8
60. Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol 2000; 18 (22): 3758-67
61. Bonneterre J, Thurlimann B, Robertson JFR, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or Arimidex randomized study group efficacy and tolerability study. J Clin Oncol 2000; 18 (22): 3748-57